SAROGLITAZAR: A NOVEL DUAL ACTING PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) IN DYSLIPIDEMIA ASSOCIATED WITH T2DM

Krishna, Ayesha Vaseem, Ravinder K. Sah* and Mazher Ali

ABSTRACT

Diabetes is a common occurrence all over the world. It results in cardiovascular complications which lead to high mortality especially in developing countries. The development of drugs which control hyperglycemia as well as dyslipidemia in diabetes is an area of extensive research. Saroglitazar (Lipaglyn™) is the first dual PPAR agonist to hit the market, launched by an Indian pharmaceutical company in 2013. Lipaglyn™ is well absorbed orally and has a non-renal route of elimination. It is well tolerated, not associated with adverse effects like edema, weight gain, myopathies or derangement of liver and/or kidney functions, thus making it safe and efficacious. At a dose of 4 mg once daily, it reduces triglycerides and LDL cholesterol, it increases HDL cholesterol, and also shows a reduction in Fasting plasma glucose. Saroglitazar provides safe and effective alternative for the treatment of diabetic dyslipidemia. Though large studies are yet needed for long term safety.

Keywords: Diabetes mellitus, Diabetic dyslipidemia, Saroglitazar.